106 related articles for article (PubMed ID: 8578256)
41. Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma.
Cai T; Nesi G; Boddi V; Mazzoli S; Dal Canto M; Bartoletti R
Oncol Rep; 2006 Aug; 16(2):329-34. PubMed ID: 16820911
[TBL] [Abstract][Full Text] [Related]
42. Bladder cancer diagnosis and recurrence prognosis: comparison of markers with emphasis on survivin.
Schultz IJ; Witjes JA; Swinkels DW; de Kok JB
Clin Chim Acta; 2006 Jun; 368(1-2):20-32. PubMed ID: 16480698
[TBL] [Abstract][Full Text] [Related]
43. Predicting recurrence and progression in non-muscle-invasive bladder cancer using European organization of research and treatment of cancer risk tables.
Ather MH; Zaidi M
Urol J; 2009; 6(3):189-93. PubMed ID: 19711273
[TBL] [Abstract][Full Text] [Related]
44. Prognosis in carcinoma of the urinary bladder based upon tissue blood group abh and Thomsen-Friedenreich antigen status and karyotype of the initial tumor.
Summers JL; Coon JS; Ward RM; Falor WH; Miller AW; Weinstein RS
Cancer Res; 1983 Feb; 43(2):934-9. PubMed ID: 6848204
[TBL] [Abstract][Full Text] [Related]
45. [The study of ABH isoantigen and T (Thomsen-Friedenreich) antigen of superficial urothelial tumor].
Sasaki K
Hokkaido Igaku Zasshi; 1984 Nov; 59(6):679-89. PubMed ID: 6530208
[TBL] [Abstract][Full Text] [Related]
46. Thymidine phosphorylase expression as a prognostic marker for predicting recurrence in primary superficial bladder cancer.
Aoki S; Yamada Y; Nakamura K; Taki T; Tobiume M; Honda N
Oncol Rep; 2006 Aug; 16(2):279-84. PubMed ID: 16820903
[TBL] [Abstract][Full Text] [Related]
47. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples.
Dahse R; Utting M; Werner W; Schimmel B; Claussen U; Junker K
Int J Oncol; 2002 Jan; 20(1):107-15. PubMed ID: 11743649
[TBL] [Abstract][Full Text] [Related]
48. Centrosome hyperamplification predicts progression and tumor recurrence in bladder cancer.
Yamamoto Y; Matsuyama H; Furuya T; Oga A; Yoshihiro S; Okuda M; Kawauchi S; Sasaki K; Naito K
Clin Cancer Res; 2004 Oct; 10(19):6449-55. PubMed ID: 15475431
[TBL] [Abstract][Full Text] [Related]
49. [The study on Thomsen-Friedenreich antigen in bladder tumor].
Oda Y
Hinyokika Kiyo; 1985 Mar; 31(3):407-18. PubMed ID: 3895852
[TBL] [Abstract][Full Text] [Related]
50. A molecular signature in superficial bladder carcinoma predicts clinical outcome.
Dyrskjøt L; Zieger K; Kruhøffer M; Thykjaer T; Jensen JL; Primdahl H; Aziz N; Marcussen N; Møller K; Orntoft TF
Clin Cancer Res; 2005 Jun; 11(11):4029-36. PubMed ID: 15930337
[TBL] [Abstract][Full Text] [Related]
51. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates.
Crew JP; O'Brien T; Bicknell R; Fuggle S; Cranston D; Harris AL
J Urol; 1999 Mar; 161(3):799-804. PubMed ID: 10022687
[TBL] [Abstract][Full Text] [Related]
52. [Non-invasive molecular detection of bladder cancer].
Hatachmi S
Harefuah; 2009 Jan; 148(1):66-9, 86. PubMed ID: 19320394
[TBL] [Abstract][Full Text] [Related]
53. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
Mahnken A; Kausch I; Feller AC; Krüger S
Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
[TBL] [Abstract][Full Text] [Related]
54. Carcinoma in a bladder diverticulum: presentation and treatment outcome.
Golijanin D; Yossepowitch O; Beck SD; Sogani P; Dalbagni G
J Urol; 2003 Nov; 170(5):1761-4. PubMed ID: 14532771
[TBL] [Abstract][Full Text] [Related]
55. Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder.
Dinney CP; Babkowski RC; Antelo M; Perrotte P; Liebert M; Zhang HZ; Palmer J; Veltri RW; Katz RL; Grossman HB
J Urol; 1998 Oct; 160(4):1285-90. PubMed ID: 9751337
[TBL] [Abstract][Full Text] [Related]
56. Conservative management of low risk superficial bladder tumors.
Pruthi RS; Baldwin N; Bhalani V; Wallen EM
J Urol; 2008 Jan; 179(1):87-90; discussion 90. PubMed ID: 17997444
[TBL] [Abstract][Full Text] [Related]
57. Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder.
Krüger S; Mess F; Böhle A; Feller AC
Int J Oncol; 2003 Jul; 23(1):41-8. PubMed ID: 12792774
[TBL] [Abstract][Full Text] [Related]
58. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
[TBL] [Abstract][Full Text] [Related]
59. Bladder tumours: time for a paradigm shift?
Malmström PU
BJU Int; 2011 May; 107(10):1543-5. PubMed ID: 21518416
[TBL] [Abstract][Full Text] [Related]
60. Thomsen-Friedenreich antigen in bladder tumors as detected by specific antibody: a possible marker of recurrence.
Ohoka H; Shinomiya H; Yokoyama M; Ochi K; Takeuchi M; Utsumi S
Urol Res; 1985; 13(2):47-50. PubMed ID: 4012935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
